Jane Street Group LLC Decreases Position in Acelyrin, Inc. (NASDAQ:SLRN)

Jane Street Group LLC trimmed its holdings in shares of Acelyrin, Inc. (NASDAQ:SLRN) by 56.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 89,800 shares of the company’s stock after selling 114,237 shares during the quarter. Jane Street Group LLC owned 0.09% of Acelyrin worth $443,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in SLRN. The Manufacturers Life Insurance Company grew its position in Acelyrin by 16.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,769 shares of the company’s stock worth $131,000 after purchasing an additional 4,163 shares during the last quarter. US Bancorp DE grew its holdings in shares of Acelyrin by 77.1% during the third quarter. US Bancorp DE now owns 16,854 shares of the company’s stock valued at $83,000 after buying an additional 7,336 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Acelyrin by 65.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 19,196 shares of the company’s stock valued at $95,000 after buying an additional 7,560 shares during the last quarter. HighTower Advisors LLC acquired a new position in shares of Acelyrin in the 3rd quarter valued at $50,000. Finally, Principal Financial Group Inc. purchased a new position in shares of Acelyrin in the second quarter worth about $49,000. 87.31% of the stock is currently owned by hedge funds and other institutional investors.

Acelyrin Stock Performance

Acelyrin stock opened at $3.49 on Tuesday. The stock has a market capitalization of $350.14 million, a P/E ratio of -1.42 and a beta of 1.94. Acelyrin, Inc. has a 1 year low of $3.05 and a 1 year high of $8.89. The company’s fifty day moving average price is $4.45 and its 200 day moving average price is $4.90.

Analyst Ratings Changes

SLRN has been the subject of a number of recent research reports. Wells Fargo & Company reduced their price target on shares of Acelyrin from $15.00 to $13.00 and set an “overweight” rating for the company in a research report on Wednesday, December 11th. HC Wainwright reiterated a “neutral” rating and issued a $8.00 target price on shares of Acelyrin in a research note on Wednesday, December 11th.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.